Cite
HARVARD Citation
Laszlo, G. et al. (2015). High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of hematology & oncology. 8 (1), pp. 1-10. [Online].